Eddie Hickman
Stock Analyst at Guggenheim
(3.26)
# 959
Out of 4,896 analysts
16
Total ratings
43.75%
Success rate
7.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $78 → $84 | $39.83 | +110.90% | 8 | May 2, 2025 | |
| PMN ProMIS Neurosciences | Reiterates: Buy | $6 | $0.40 | +1,399.63% | 2 | Apr 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $11.93 | +84.41% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $15.42 | +107.52% | 1 | Mar 13, 2025 | |
| CYBN Cybin | Initiates: Buy | $35 | $7.49 | +367.29% | 1 | Mar 13, 2025 | |
| OTLK Outlook Therapeutics | Reiterates: Buy | $12 | $2.06 | +483.94% | 3 | Jan 17, 2025 |
Tarsus Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $78 → $84
Current: $39.83
Upside: +110.90%
ProMIS Neurosciences
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.40
Upside: +1,399.63%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $11.93
Upside: +84.41%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $15.42
Upside: +107.52%
Cybin
Mar 13, 2025
Initiates: Buy
Price Target: $35
Current: $7.49
Upside: +367.29%
Outlook Therapeutics
Jan 17, 2025
Reiterates: Buy
Price Target: $12
Current: $2.06
Upside: +483.94%